Culmination Bio, a data and technology company combining clinical and biospecimen data, entered a R&D collaboration with Merck in the area of autoimmune disease.     Merck will have access to both clinical (Electronic Health Records, labs, medications) and paired biospecimen (tissue and blood) data from several cohorts of various sizes and qualifications. The project-based collaboration leverages Culmination’s ability to build both retrospective and prospective deidentified multi-modal dat...